drugset / Trial / NCT00571116
Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial is studying the side effects and best dose of arsenic trioxide when given together with disulfiram in treating patients with metastatic and progressive melanoma. Drugs used in chemotherapy, such as disulfiram and arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
Timeline
- Start
- 2006-09
- Primary completion
- 2012-08
- Completion
- 2012-08
Outcome
Outcome not reported
Stopped (Enrollment): “Halted because of slow accrual and lack of study funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Disulfiram | Small molecule | 250 mg | Oral |
| Subject | arsenic trioxide | Small molecule | 0.05 mg/kg | Intravenous |
| Subject | arsenic trioxide | Small molecule | 0.1 mg/kg | Intravenous |
| Subject | arsenic trioxide | Small molecule | 0.15 mg/kg | Intravenous |